Sir, Vancomycin resistance among enterococcal bloodstream isolates in Europe is relatively low (0.1-3.5%).
1,2 Among isolates from non-sterile body sites in Hungary, Poland, Czech Republic and Slovakia rates of 1-3% [1] [2] [3] have been reported, whilst resistance in Austria is minimal (0-1%). 4 The first signs of an increasing incidence of vancomycinresistant enterococci (VRE) was reported from University Hospital Haematology and Oncology departments in Olomouc and Ostrava in 1999, where the proportion of VRE in Enterococcus faecium increased to 10%, whilst E. faecium represented 12.5% of all isolates. 5, 6 However, VRE screening was not performed in these studies [1] [2] [3] [4] [5] [6] (Table) .
A nationwide survey of enterococcal bacteraemia in Slovakia was therefore undertaken. All episodes of enterococcal bacteraemia between 1 January 1997 and 1 January 2000 (3 years) in all six university hospitals were reviewed. Two of six university hospitals were patient specific (cancer, respiratory), whilst the other four were general hospitals. One-hundred and thirty-two enterococcal bloodstream infection episodes were identified and 45 of 132 patients (34%) died. Antibiotic susceptibilities in VRE were confirmed by the National Reference Laboratory of Antibiotic Resistance of the Ministry of Health. The National Committee for Clinical and Laboratory Standards (NCCLS)-recommended disc diffusion method for testing of antibiotics was used in all local laboratories and in the reference laboratory.
Strains from blood cultures were isolated by a semiautomated system (Bactec or Bact-Alert) and identified with the Vitek Jr system (bioMérieux, Hazelwood, MI, USA). E. faecium were identified with API 20 STREP (bioMérieux, Marcy l'Etoile, France). DNA fingerprinting was not performed. Among 132 enterococcal bacteraemias detected, VRE accounted for 6.8% and teicoplanin resistance was found in 5.3% of all enterococcal bloodstream isolates (88.6% Enterococcus faecalis, 9.1% E. faecium, 4.3% Enterococcus gallinarum). However, vancomycin resistance in E. faecium was 33.3% and teicoplanin resistance 16.7% (Table) . Resistance to chloramphenicol, tetracycline, ampicillin and gentamicin was higher among strains of E. faecium than in E. faecalis (Table) .
Our survey has shown 6.8% vancomycin resistance and 5.3% teicoplanin resistance among bloodstream isolates. Therefore nationwide surveys in other Central/Eastern European countries including Russia, Ukraine and the Baltic republics, on the epidemiology of glycopeptide resistance are needed. Table VAN , vancomycin; TEI, teicoplanin; CMP, chloramphenicol; TET, tetracycline; AMP, ampicillin; GEN, gentamicin; AMI, ampicillin; COT, co-trimoxazole.
